Oral Contraceptive Drugs Capture Around 50% Value Share

Oral contraceptives are highly preferable as a first-line treatment for patients without contraindications, on grounds of their efficacy in preventing recurrence of pelvic pain and endometriosis lesions. However, they are associated with possible side effects such as mood changes, nausea, and elevated blood pressure levels. Progestins, on the other hand, require to be consumed periodically, unlike oral contraceptives, which require regular consumption.

By 2029, the drug category will represent a billion-dollar opportunity. Furthermore, market players are unlocking new revenue streams in gonadotropin-releasing hormone (GnRH) analogues for relevant value creation.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Opportunities Prevail in Developed Regions

Europe and North America will maintain their supremacy in the global endometriosis treatment market, with the latter expected to cross US$ 1 Bn in 2020. Incumbents are pairing with healthcare providers to raise awareness in the field of endometriosis at physician and patient levels.

Endometriosis Treatment Market

While these developed regional markets maintain a positive trend, stakeholders are eyeing Asia for further revenue lines. Governments in China and India are significantly increasing their healthcare budgets in order to reach the unmet sections of society.

Advanced Drug Delivery Technologies to Propel Market Growth

Oral contraceptives have been the conventional drug category for treating endometriosis. Yet, they carry the drawback of first-pass liver metabolism. Market players are rolling out novel transdermal drug delivery technologies such as topical applicators to enhance efficacy and overcome the disadvantages of oral contraceptives.

Moreover, these advanced drug delivery technologies achieve steady serum hormone concentration, and thus, are expected to become commonplace in endometriosis treatment. For instance, Noven has developed CombiPatch®, a combination (two-drug) patch that can be effectively used in endometriosis treatment.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How Growth will Unfold

Market player continue to bank on hormonal therapy to stay ahead of their peers in the endometriosis treatment market. FMI finds that, around 9 out of 10 medical professionals prefer hormonal replacement therapy for treating endometriosis, attributable to its enhanced effectiveness with minimum risks of breast cancer.

Endometriosis Treatment Market

That being said, patients undergoing the treatment are subject to post-therapy complications such as bloating, indigestion, and leg cramps. As such, they are turning to other options, including pain management.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

Treatment Type:

  • Hormonal Therapy
  • Pain Management

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • e-Commerce

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Frequently Asked Questions

What is the Growth Outlook for Endometriosis Treatment Market?

The endometriosis treatment market is likely to secure a CAGR of 10.6% through 2032.

By 2032, how much can the Endometriosis Treatment Market Grow?

The endometriosis treatment market size is estimated to cross US$ 3.55 Billion by 2032.

What is the Current Valuation of the Endometriosis Treatment Market?

The endometriosis treatment market is likely to record a value of US$ 1.30 Billion in 2022.

Which Region is likely to Lead the Endometriosis Treatment Market?

Europe is likely to lead the endometriosis treatment market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Drug Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Endometriosis Epidemiology, By Key Region

    4.3. Unmet Needs of Endometriosis Treatment

        4.3.1. Potential Diagnostic Biomarkers for Endometriosis

            4.3.1.1. Existing & Emerging Non-invasive Diagnostics Techniques

        4.3.2. Disease Awareness and Educational Strategies for Medical Professionals

        4.3.3. Drug Effectivity & Safety, By Drug

        4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis

        4.3.5. Disease Etiology and Pathophysiology

    4.4. Research and Development Strategies

        4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs

        4.4.2. Pipeline Assessment of GnRH Antagonists

        4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies

        4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies)

        4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication)

    4.5. Attributes/Factors Important in Clinical Trials 

    4.6. Clinical Trial History of Key Marketed Drugs

    4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs

    4.8. Pipeline Assessment/Clinical Benchmark Analysis

        4.8.1. Marketed Drug/Pipeline Valuation Analysis 

            4.8.1.1. Therapeutic Advantages by Drug

            4.8.1.2. New Drug Launches and Regulatory Approvals, 2019-2030

            4.8.1.3. Opportunity Assessment in terms of Revenue, 2020-2025

            4.8.1.4. Clinical Trials and Pipeline Overview

    4.9. Regulatory Scenario

    4.10. Reimbursement Scenario

    4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities

5. Global Market Demand (Size in US$ Mn) Analysis 2014-2018 and Opportunity Assessment, 2019-2030

    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018

    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2030

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Outlook 

        6.1.3. Per Capita Healthcare Expenditure Outlook

    6.2. Opportunity Assessment Factors - Relevance & Impact

        6.2.1. Prevalence of Endometriosis

        6.2.2. Growing Healthcare Expenditure

        6.2.3. Increasing Number of Clinical Trials

        6.2.4. Regulatory Policy Changes

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

7. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Drug

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Drug, 2014-2018

    7.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Drug, 2019-2030

        7.3.1. Oral Contraceptives

        7.3.2. Progestins

        7.3.3. NSAIDs

        7.3.4. GnRH Analogues

        7.3.5. LNR-IUDs

        7.3.6. Others

    7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Treatment Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014-2018

    8.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Treatment Type, 2019-2030

        8.3.1. Hormonal Therapy

        8.3.2. Pain management 

    8.4. Market Attractiveness Analysis By Treatment Type

9. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014-2018

    9.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Distribution Channel, 2019-2030

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Drugstores

        9.3.4. E-commerce

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Market Analysis 2014-2018 and Opportunity Assessment 2019-2030, by Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018

    10.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Region, 2019-2030

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    11.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug

        11.3.3. By Treatment Type

        11.3.4. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Drug

        11.4.3. By Treatment Type

        11.4.4. By Distribution Channel

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    12.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug

        12.3.3. By Treatment Type

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug

        12.4.3. By Treatment Type

        12.4.4. By Distribution Channel

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    13.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        13.3.1.  By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug

        13.3.3. By Treatment Type

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug

        13.4.3. By Treatment Type

        13.4.4. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    14.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        14.3.1.  By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Drug

        14.3.3. By Treatment Type

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug

        14.4.3. By Treatment Type

        14.4.4. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    15.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        15.3.1.  By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug

        15.3.3. By Treatment Type

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Treatment Type

        15.4.4. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    16.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        16.3.1.  By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug

        16.3.3. By Treatment Type

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Treatment Type

        16.4.4. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    17.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        17.3.1.  By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. Northern Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Drug

        17.3.3. By Treatment Type

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Treatment Type

        17.4.4. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Emerging Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. India Market Analysis

        18.2.1. Introduction

        18.2.2. PEST Analysis

        18.2.3. Market Value Analysis by Market Taxonomy

        18.2.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

            18.2.4.1. By Drug

            18.2.4.2. By Treatment Type

            18.2.4.3. By Distribution Channel

    18.3. China Market Analysis

        18.3.1. Introduction

        18.3.2. PEST Analysis

        18.3.3. Market Value Analysis by Market Taxonomy

        18.3.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

            18.3.4.1. Drug

            18.3.4.2. By Treatment Type

            18.3.4.3. By Distribution Channel

    18.4. Brazil Market Analysis

        18.4.1. Introduction

        18.4.2. PEST Analysis

        18.4.3. Market Value Analysis by Market Taxonomy

        18.4.4. Market Value (US$ Mn) Analysis and Opportunity Assessment by Market Taxonomy

            18.4.4.1. By Drug

            18.4.4.2. By Treatment Type

            18.4.4.3. By Distribution Channel

19. U.S. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    19.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        19.3.1. By Drug

        19.3.2. By Treatment Type

        19.3.3. By Distribution Channel

    19.4. Market Attractiveness Analysis

20. Canada Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    20.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        20.3.1. By Drug

        20.3.2. By Treatment Type

        20.3.3. By Distribution Channel

    20.4. Market Attractiveness Analysis

21. Mexico Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    21.1. Introduction

    21.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    21.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        21.3.1. By Drug

        21.3.2. By Treatment Type

        21.3.3. By Distribution Channel

    21.4. Market Attractiveness Analysis

22. Germany Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    22.1. Introduction

    22.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    22.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        22.3.1. By Drug

        22.3.2. By Treatment Type

        22.3.3. By Distribution Channel

    22.4. Market Attractiveness Analysis

23. U.K. Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    23.1. Introduction

    23.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    23.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        23.3.1. By Drug

        23.3.2. By Treatment Type

        23.3.3. By Distribution Channel

    23.4. Market Attractiveness Analysis

24. France Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    24.1. Introduction

    24.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    24.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        24.3.1. By Drug

        24.3.2. By Treatment Type

        24.3.3. By Distribution Channel

    24.4. Market Attractiveness Analysis

25. Italy Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    25.1. Introduction

    25.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    25.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        25.3.1. By Drug

        25.3.2. By Treatment Type

        25.3.3. By Distribution Channel

    25.4. Market Attractiveness Analysis

26. Spain Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    26.1. Introduction

    26.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    26.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        26.3.1. By Drug

        26.3.2. By Treatment Type

        26.3.3. By Distribution Channel

    26.4. Market Attractiveness Analysis

27. Russia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    27.1. Introduction

    27.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    27.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        27.3.1. By Drug

        27.3.2. By Treatment Type

        27.3.3. By Distribution Channel

    27.4. Market Attractiveness Analysis

    27.5. Market Attractiveness Analysis

28. Japan Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    28.1. Introduction

    28.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    28.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        28.3.1. By Drug

        28.3.2. By Treatment Type

        28.3.3. By Distribution Channel

    28.4. Market Attractiveness Analysis

29. South Korea Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    29.1. Introduction

    29.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    29.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        29.3.1. By Drug

        29.3.2. By Treatment Type

        29.3.3. By Distribution Channel

    29.4. Market Attractiveness Analysis

30. Australia Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    30.1. Introduction

    30.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    30.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        30.3.1. By Drug

        30.3.2. By Treatment Type

        30.3.3. By Distribution Channel

    30.4. Market Attractiveness Analysis

31. New Zealand Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    31.1. Introduction

    31.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    31.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        31.3.1. By Drug

        31.3.2. By Treatment Type

        31.3.3. By Distribution Channel

    31.4. Market Attractiveness Analysis

32. GCC Countries Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    32.1. Introduction

    32.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    32.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        32.3.1. By Drug

        32.3.2. By Treatment Type

        32.3.3. By Distribution Channel

    32.4. Market Attractiveness Analysis

33. South Africa Market Analysis 2014-2018 and Opportunity Assessment 2019-2030

    33.1. Introduction

    33.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014-2018

    33.3. Current and Future Market Size (US$ Mn) Analysis and Opportunity Assessment By Market Taxonomy, 2019-2030

        33.3.1. By Drug

        33.3.2. By Treatment Type

        33.3.3. By Distribution Channel

    33.4. Market Attractiveness Analysis

34. Market Structure Analysis

    34.1. Market Analysis by Tier of Companies 

    34.2. Market Share Analysis of Top Players

    34.3. Company Share Analysis

    34.4. Market Presence Analysis

        34.4.1. By Regional footprint of Players

        34.4.2. Channel Foot Print by Players

35. Competition Analysis

    35.1. Competition Dashboard

    35.2. Competition Benchmarking

    35.3. Competition Deep Dive (Tentative List)

        35.3.1. AbbVie Inc.

            35.3.1.1. Overview

            35.3.1.2. Service Portfolio

            35.3.1.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.1.4. Sales Footprint

            35.3.1.5. Strategy Overview

                35.3.1.5.1. Marketing Strategy

                35.3.1.5.2. Service Strategy

                35.3.1.5.3. Channel Strategy

        35.3.2. Bayer AG

            35.3.2.1. Overview

            35.3.2.2. Service Portfolio

            35.3.2.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.2.4. Sales Footprint

            35.3.2.5. Strategy Overview

                35.3.2.5.1. Marketing Strategy

                35.3.2.5.2. Service Strategy

                35.3.2.5.3. Channel Strategy

        35.3.3. AstraZeneca

            35.3.3.1. Overview

            35.3.3.2. Service Portfolio

            35.3.3.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.3.4. Sales Footprint

            35.3.3.5. Strategy Overview

                35.3.3.5.1. Marketing Strategy

                35.3.3.5.2. Service Strategy

                35.3.3.5.3. Channel Strategy

        35.3.4. Pfizer Inc.

            35.3.4.1. Overview

            35.3.4.2. Service Portfolio

            35.3.4.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.4.4. Sales Footprint

            35.3.4.5. Strategy Overview

                35.3.4.5.1. Marketing Strategy

                35.3.4.5.2. Service Strategy

                35.3.4.5.3. Channel Strategy

        35.3.5. Teva Pharmaceutical Industries Ltd.

            35.3.5.1. Overview

            35.3.5.2. Service Portfolio

            35.3.5.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.5.4. Sales Footprint

            35.3.5.5. Strategy Overview

                35.3.5.5.1. Marketing Strategy

                35.3.5.5.2. Service Strategy

                35.3.5.5.3. Channel Strategy

        35.3.6. Ipsen Pharma

            35.3.6.1. Overview

            35.3.6.2. Service Portfolio

            35.3.6.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.6.4. Sales Footprint

            35.3.6.5. Strategy Overview

                35.3.6.5.1. Marketing Strategy

                35.3.6.5.2. Service Strategy

                35.3.6.5.3. Channel Strategy

        35.3.7. Myovant Sciences

            35.3.7.1. Overview

            35.3.7.2. Service Portfolio

            35.3.7.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.7.4. Sales Footprint

            35.3.7.5. Strategy Overview

                35.3.7.5.1. Marketing Strategy

                35.3.7.5.2. Service Strategy

                35.3.7.5.3. Channel Strategy

        35.3.8. Endoceutics, Inc.

            35.3.8.1. Overview

            35.3.8.2. Service Portfolio

            35.3.8.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.8.4. Sales Footprint

            35.3.8.5. Strategy Overview

                35.3.8.5.1. Marketing Strategy

                35.3.8.5.2. Service Strategy

                35.3.8.5.3. Channel Strategy

        35.3.9. Debiopharm Group

            35.3.9.1. Overview

            35.3.9.2. Service Portfolio

            35.3.9.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.9.4. Sales Footprint

            35.3.9.5. Strategy Overview

                35.3.9.5.1. Marketing Strategy

                35.3.9.5.2. Service Strategy

                35.3.9.5.3. Channel Strategy

        35.3.10. Mayne Pharma Group Limited

            35.3.10.1. Overview

            35.3.10.2. Service Portfolio

            35.3.10.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.10.4. Sales Footprint

            35.3.10.5. Strategy Overview

                35.3.10.5.1. Marketing Strategy

                35.3.10.5.2. Service Strategy

                35.3.10.5.3. Channel Strategy

        35.3.11. Noven Pharmaceuticals, Inc.

            35.3.11.1. Overview

            35.3.11.2. Service Portfolio

            35.3.11.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.11.4. Sales Footprint

            35.3.11.5. Strategy Overview

                35.3.11.5.1. Marketing Strategy

                35.3.11.5.2. Service Strategy

                35.3.11.5.3. Channel Strategy

        35.3.12. Sun Pharmaceutical Industries Limited

            35.3.12.1. Overview

            35.3.12.2. Service Portfolio

            35.3.12.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.12.4. Sales Footprint

            35.3.12.5. Strategy Overview

                35.3.12.5.1. Marketing Strategy

                35.3.12.5.2. Service Strategy

                35.3.12.5.3. Channel Strategy

        35.3.13. Amneal Pharmaceuticals, Inc. Market_Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2030

            35.3.13.1. Overview

            35.3.13.2. Service Portfolio

            35.3.13.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.13.4. Sales Footprint

            35.3.13.5. Strategy Overview

                35.3.13.5.1. Marketing Strategy

                35.3.13.5.2. Service Strategy

                35.3.13.5.3. Channel Strategy

        35.3.14. Mylan N.V.

            35.3.14.1. Overview

            35.3.14.2. Service Portfolio

            35.3.14.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.14.4. Sales Footprint

            35.3.14.5. Strategy Overview

                35.3.14.5.1. Marketing Strategy

                35.3.14.5.2. Service Strategy

                35.3.14.5.3. Channel Strategy

        35.3.15. Aurobindo Pharma

            35.3.15.1. Overview

            35.3.15.2. Service Portfolio

            35.3.15.3. Profitability by Market Segments (Service/Channel/Region)

            35.3.15.4. Sales Footprint

            35.3.15.5. Strategy Overview

                35.3.15.5.1. Marketing Strategy

                35.3.15.5.2. Service Strategy

                35.3.15.5.3. Channel Strategy

36. Assumptions and Acronyms Used

37. Research Methodology

Explore Healthcare Insights

View Reports
Future Market Insights

Endometriosis Treatment Market